Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28591026 | 0.96 | RAB9A (0.66) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL13969475 | 0.94 | RAB9A (0.64) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL7489809 | 0.93 | HPGD (0.70) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL30084003 | 0.93 | HPGD (0.70) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL12413497 | 0.88 | HEXA (0.61) | RAB9AMAPTSMN1; SMN2POLBHSD17B10 | |
| SCHEMBL4728037 | 0.87 | HPGD (0.59) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL24153517 | 0.87 | RAB9A (0.66) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL5277782 | 0.85 | RAB9A (0.67) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL7299163 | 0.84 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL8298007 | 0.83 | RAB9A (0.79) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542267-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2023-01-03 | — | — | US | disclosed |
| US-11535623-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2022-12-27 | — | — | US | disclosed |
| US-11535623-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2022-12-27 | — | — | US | disclosed |
| US-20200308183-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-20200308183-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-10717741-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-07-21 | — | — | US | disclosed |
| US-10717741-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-07-21 | — | — | US | disclosed |
| EP-2729467-B1 | CRYPTATE COMPOUNDS AND METHODS FOR THEIR PREPARATION | AUSTRALIAN NUCLEAR SCIENCE TEC (AU) | 2016-10-12 | — | — | EP | disclosed |
| US-9249306-B2 | Quenched dendrimeric dyes for florescence detection | CARNEGIE MELLON UNIVERSITY (US) | 2016-02-02 | — | — | US | disclosed |
| EP-1506208-A4 | 1,1- AND 1,2-BISPHOSPHONATES AS APOLIPOPROTEIN E MODULATORS | ILEX PRODUCTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1506208-A2 | 1,1- AND 1,2-BISPHOSPHONATES AS APOLIPOPROTEIN E MODULATORS | Ilex Products, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094851-A2 | 1,1- AND 1,2-BISPHOSPHONATES AS APOLIPROTEIN E MODULATORS | ILEX PRODUCTS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-5962460-A | CONTROLLING CANCER GROWTH | NATIONAL SCIENCE COUNCIL (TAIWAN) (TW) | 1999-10-05 | — | — | US | disclosed |
| US-5478851-A | Hyperglycemic agent and antilipemic agent | BEECHAM GROUP PLC (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0555264-A1 | NOVEL COMPOUNDS | BEECHAM GROUP plc (GB) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007850-A1 | NOVEL COMPOUNDS | BEECHAM GROUP PLC (GB) | 1992-05-14 | — | — | WO | disclosed |
| US-4764612-A | SELECTIVE HISTAMINE H2-ANTAGONIST | GLAXO GROUP LIMITED (GB) | 1988-08-16 | — | — | US | disclosed |
| US-4442110-A | ANTISECRETORY, ANTIALLERGEN, ANTIINFLAMMATORY, ANTIULCER | GLAXO GROUP LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
| US-4318913-A | 1,2,4-Triazole-3,5-diamine derivatives | GLAXO GROUP LIMITED (GB) | 1982-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308183-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | RAB9A 2192/4885MAPT 3255/4885SMN1; SMN2 3013/4885 |
| US-11542267-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | RAB9A 2192/4885MAPT 3255/4885SMN1; SMN2 3013/4885 |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | RAB9A 2192/4885MAPT 3255/4885SMN1; SMN2 3013/4885 |
| US-10717741-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | RAB9A 2192/4885MAPT 3255/4885SMN1; SMN2 3013/4885 |
| US-11535623-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | RAB9A 2192/4885MAPT 3255/4885SMN1; SMN2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.